Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled date : 2021 - 10 - 26 save search
Guardhat Launches Advisory Board With Deep Expertise in Industrial Operations; Adds First Two Members
Published: 2021-10-26 (Crawled : 22:00) - prnewswire.com
GATX 4 | $125.83 -0.23% 0.0% 150K
|
Finance
|
| O: 0.63%
H: 0.84%
C: -2.36%
trial
Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit
Published: 2021-10-26 (Crawled : 22:00) - biospace.com/
NRIX 6 d | $13.75 -2.69% -2.91% 520K
|
Health Technology
|
| O: 1.13%
H: 0.0%
C: 0.0%
phase 1 trial t-cell
STAG Industrial Refinances Unsecured $750 Million Credit Facility, Refinances Unsecured $150 Million Term Loan, And Reprices $675 Million Of Unsecured Debt
Published: 2021-10-26 (Crawled : 20:00) - prnewswire.com
STAG | $34.75 -1.86% 0.6% 1.3M
|
Finance
|
| O: 0.65%
H: 0.14%
C: -1.42%
RY | News 4 d | $97.27 -1.59% 0.0% 3.5M
|
Finance
|
| O: -0.55%
H: 0.69%
C: -0.71%
trial
Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody, in the Treatment of Generalized Pustular Psoriasis: Results from a Phase 2 Trial
Published: 2021-10-26 (Crawled : 20:00) - anaptysbio.com
ANAB | $19.27 0.47% 0.36% 390K
|
Health Technology
|
| O: 5.47%
H: 2.32%
C: 0.23%
psoriasis treatment phase 2 results antibody trial
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
Published: 2021-10-26 (Crawled : 17:00) - biospace.com/
KRYS | News | $159.05 -1.85% -1.88% 240K
|
Health Technology
|
| O: 1.27%
H: 0.0%
C: 0.0%
treatment biotech phase 3 iot
Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer
Published: 2021-10-26 (Crawled : 17:00) - biospace.com/
ALKS | $24.65 1.61% 1.62% 1.7M
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: 0.0%
cancer nemvaleukin phase 3 ovarian cancer trial
BioVie Announces FDA Authorization to Initiate Phase 2 Trials Assessing NE3107’s Pro-motoric Activity in Parkinson’s Disease
Published: 2021-10-26 (Crawled : 14:15) - biospace.com/
BIVI | $0.5054 2.77% 2.13% 830K
|
Health Technology
|
| O: 6.04%
H: 0.0%
C: 0.0%
disease fda phase 2 parkinson trials trial
New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery
Published: 2021-10-26 (Crawled : 14:00) - biospace.com/
VCYT | News | $19.9 0.35% 0.45% 510K
|
Health Technology
|
| O: -1.13%
H: 0.0%
C: 0.0%
NSTG M | $0.1053 -37.43% -0.19% 0
|
Health Technology
|
| O: 0.39%
H: 0.0%
C: 0.0%
treatment prostate cancer genomic cancer
INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa
Published: 2021-10-26 (Crawled : 13:00) - biospace.com/
INO | $10.16 -2.03% -2.67% 250K
|
Health Technology
|
| O: 1.15%
H: 0.0%
C: 0.0%
phase 1 phase 1b vaccine trial ino-4800 enroll phase 2b africa
Vaxart Doses First Subject in Phase II COVID-19 Oral Tablet Vaccine Clinical Trial
Published: 2021-10-26 (Crawled : 13:00) - biospace.com/
VXRT | News | $0.7097 -4.79% -5.72% 1.4M
|
Health Technology
|
| O: 1.16%
H: 0.0%
C: 0.0%
covid vaccine trial covid-19
Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
Published: 2021-10-26 (Crawled : 12:00) - biospace.com/
CANF | $1.94 -1.52% 5.67% 5.7K
|
Health Technology
|
| O: -1.61%
H: 0.0%
C: 0.0%
drug ceo trial namodenoson
Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scientific Meeting
Published: 2021-10-26 (Crawled : 12:00) - biospace.com/
MCRB | $0.7295 -4.01% -4.18% 5.7M
|
Health Technology
|
| O: -3.24%
H: 0.0%
C: 0.0%
phase 3 injection infections
Hubbell Announces Sale of Commercial and Industrial Lighting Business
Published: 2021-10-26 (Crawled : 12:00) - globenewswire.com
MS | News 0 d | $93.85 0.1% -0.02% 3.3M
|
Finance
|
| O: 0.33%
H: 0.0%
C: 0.0%
HUBB | News | $398.55 0.14% 0.0% 340K
|
Producer Manufacturing
|
| O: -5.46%
H: 0.0%
C: 0.0%
trial sales commercialization
Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
Published: 2021-10-26 (Crawled : 11:00) - biospace.com/
ZYME | $8.55 -0.12% -0.06% 240K
|
Health Technology
|
| O: 1.77%
H: 0.0%
C: 0.0%
test cancer gastrointestinal trial commercialization designation
4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia
Published: 2021-10-25 (Crawled : 00:00) - biospace.com/
FDMT M | $24.25 -2.26% -2.29% 290K
|
Health Technology
|
| O: 0.22%
H: 2.43%
C: 1.48%
disease phase 1 results molecular trial phase 2 phase 3
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.